文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

多中心试验中对勾画与治疗计划要求的依从性:SAKK 09/10 试验质量保证结果

Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-01-03

该研究评估了 SAKK 09/10 三期随机试验的放疗质量保证项目,该试验比较 64 Gy 与 70 Gy 挽救性放疗用于前列腺切除术后生化复发的前列腺癌患者。中心回顾 344 例患者的治疗计划发现,对 EORTC 指南和试验方案推荐存在重要偏离,且偏离与急性/晚期胃肠或泌尿生殖毒性风险及生化进展自由生存趋势相关。

要点

  • 在多达一半的病例中,勾画结构偏离方案,例如前列腺床偏离占 48.8%,直肠壁偏离占 41%。
  • 临床靶体积(CTV)与计划靶体积(PTV)偏离频繁发生,CTV 偏离高达 42.4%,PTV 偏离高达 25.9%。
  • CTV 未与直肠壁重叠时,≥2 级急性胃肠毒性风险低于 CTV 与直肠壁重叠时(OR 0.43,95%CI 0.22-0.85,P=.014)。

核心结论

  • 尽管有完善的质量保证项目,三期试验的中心审查显示对治疗协议推荐的依从性有限,这与急性或晚期胃肠或泌尿生殖毒性风险升高相关,并显示生化进展自由生存(FFBP)有更差的趋势。

研究设计与样本

  • 研究为 SAKK 09/10 三期随机试验的放疗质量保证项目评估,该试验测试 64 Gy 对比 70 Gy 挽救性放疗,纳入前列腺切除术后生化复发的前列腺癌患者。
  • 由专职医学物理师和放射肿瘤学家对治疗计划进行集中收集和彻底审查。
  • 调查了对治疗协议及 EORTC 靶体积定义指南的依从性(分类为观察到偏离是 vs 否)及其与急性和晚期毒性(CTCAE 4.0)和 FFBP 的潜在相关性。

主要发现

  • 2011 年 2 月至 2014 年 4 月治疗的 344 例患者的治疗计划显示与 EORTC 指南和试验方案推荐存在重要偏离。
  • 勾画结构偏离方案:前列腺床 48.8%,直肠壁 41%。
  • CTV 和 PTV 偏离分别高达 42.4% 和 25.9%。
  • CTV 未与直肠壁重叠 vs 重叠时,≥2 级急性胃肠毒性风险:OR 0.43(95%CI 0.22-0.85,P=.014)。
  • CTV 与直肠壁重叠时,≥2 级晚期泌尿生殖毒性风险:OR 2.58(95%CI 1.17-5.72,P=.019)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the results of the radiation therapy (RT) quality assurance (QA) program of the phase 3 randomized SAKK 09/10 trial in patients with biochemically recurrent prostate cancer after prostatectomy. METHODS AND MATERIALS: Within the Schweizerische Arbeitsgemeinschaft für Klinische Krebsforschung (SAKK) 09/10 trial testing 64-Gy versus 70-Gy salvage RT, a central collection of treatment plans was performed and thoroughly reviewed by a dedicated medical physicist and radiation oncologist. Adherence to the treatment protocol and specifically to the European Organization for the Research and Treatment of Cancer (EORTC) guidelines for target volume definition (classified as deviation observed yes vs no) and its potential correlation with acute and late toxicity (Common Terminology Criteria for Adverse Events version 4.0) and freedom from biochemical progression (FFBP) were investigated. RESULTS: The treatment plans for 344 patients treated between February 2011 and April 2014 depicted important deviations from the EORTC guidelines and the recommendations per trial protocol. For example, in up to half of the cases, the delineated structures deviated from the protocol (eg, prostate bed in 48.8%, rectal wall [RW] in 41%). In addition, variations in clinical target volume (CTV) and planning target volume (PTV) occurred frequently (eg, CTV and PTV deviations in up to 42.4% and 25.9%, respectively). The detected deviations showed a significant association with a lower risk of grade ≥2 gastrointestinal acute toxicity when the CTV did not overlap the RW versus when the CTV overlapped the RW (odds ratio [OR], 0.43; 95% confidence interval [CI], 0.22-0.85; P = .014), and a higher rate of grade ≥2 late genitourinary (GU) toxicity when the CTV overlapped the RW (OR, 2.58; 95% CI, 1.17-5.72; P = .019). A marginally significant lower risk of grade ≥2 late GU toxicity was observed when the prostate bed did not overlap versus did overlap the RW (OR, 0.51; 95% CI, 0.25-1.03; P = .06). In addition, a marginally significant decrease in FFBP was observed in patients with PTV not including surgical clips as potential markers of the limits of the prostate bed (hazard ratio, 1.44; 95% CI, 0.96-2.17; P = .07). CONCLUSIONS: Despite a thorough QA program, the central review of a phase 3 trial showed limited adherence to treatment protocol recommendations, which was associated with a higher risk of toxicity by means of acute or late gastrointestinal or GU toxicity and showed a trend toward worse FFBP. Data from this QA review might help to refine future QA programs and prostate bed delineation guidelines.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Beck M, Sassowsky M, Schär S, et al. Adherence to Contouring and Treatment Planning Requirements Within a Multicentric Trial: Results of the Quality Assurance of the SAKK 09/10 trial. Int J Radiat Oncol Biol Phys. 2022. PMID: 34990777. doi:10.1016/j.ijrobp.2021.12.174

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。